UPDATE: Barrington Research Initiates TranS1 at Outperform on Growth Outlook

Loading...
Loading...
Barrington Research initiated coverage on TranS1
TSON
with an Outperform rating and a $4 price target. Barrington Research said, "We estimate that the minimally invasive spinal fusion market is less than 30% of the total market and over the next few years, we expect the percentage of minimally invasive procedures to approach 60%. We estimate the potential lumbar spinal fusion market is well in excess of $1 billion. We believe TSON has the least invasive approach for the treatment of S1/L5/L4 and in our opinion, TSON will be a market leader of this segment as the company convinces the masses, doctor by doctor." TranS1 closed at $2.42 on Friday.
Posted In: Analyst ColorInitiationPre-Market OutlookAnalyst RatingsBarrington Research
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...